Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at StockNews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Saturday.

Several other equities analysts also recently weighed in on the company. BMO Capital Markets reissued an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 27th. Chardan Capital reduced their target price on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating on the stock in a report on Friday, February 16th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $165.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Finally, Morgan Stanley decreased their target price on shares of Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 13th. Eight analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $216.12.

Alnylam Pharmaceuticals Trading Down 2.4 %

Shares of NASDAQ ALNY opened at $148.50 on Friday. The company’s 50-day moving average price is $153.99 and its 200 day moving average price is $167.85. Alnylam Pharmaceuticals has a 52 week low of $143.52 and a 52 week high of $218.88. The stock has a market cap of $18.70 billion, a price-to-earnings ratio of -41.71 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. During the same quarter in the prior year, the company earned ($1.68) earnings per share. The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. As a group, research analysts expect that Alnylam Pharmaceuticals will post -4.61 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ALNY. Vanguard Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after acquiring an additional 287,064 shares during the period. BlackRock Inc. raised its position in Alnylam Pharmaceuticals by 0.7% in the first quarter. BlackRock Inc. now owns 8,548,962 shares of the biopharmaceutical company’s stock valued at $1,712,528,000 after purchasing an additional 59,582 shares during the period. Wellington Management Group LLP raised its position in Alnylam Pharmaceuticals by 6.0% in the third quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock valued at $1,139,074,000 after purchasing an additional 364,021 shares during the period. Capital International Investors lifted its stake in shares of Alnylam Pharmaceuticals by 15.8% during the fourth quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock worth $686,641,000 after purchasing an additional 488,814 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. boosted its position in shares of Alnylam Pharmaceuticals by 0.3% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,202,793 shares of the biopharmaceutical company’s stock worth $761,144,000 after buying an additional 10,609 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.